<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01192945</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-0905</org_study_id>
    <nct_id>NCT01192945</nct_id>
  </id_info>
  <brief_title>Non-interventional Study With Azacitidin (Vidaza®)</brief_title>
  <acronym>Piaza</acronym>
  <official_title>Piaza - Non-interventional Study on the Efficacy and Safety of Azacitidin (Vidaza®) in Patients With Myelodysplastic Syndromes (MDS, INT-2 or High Risk), AML (WHO 20-30% Blasts), or CMMoL (10-29% Bone Marrow Blasts Without Myeloproliferative Disorder)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional study is to collect data on the efficiency and safety
      of Azacitidin in the routine application.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>2 years after LPI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2 year survival rate</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment discontinuation</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>haematological improvement</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relative dosage of azacitidine</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver and kidney functionality</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood transfusion requirements</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>supportive medication</measure>
    <time_frame>2 years after LPI</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">150</enrollment>
  <condition>MDS</condition>
  <condition>AML</condition>
  <condition>CMMOL</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who are not suitable for transplantation of hematopoietic stem cells and have one
        of the following diseases: myelodysplastic syndrome (MDS) with intermediate risk 2 or high
        risk according to the International Prognostic Scoring System (IPSS), chronic
        myelomonocytic leukemia (CMML) with 10-29% marrow blasts without myeloproliferative
        disorder, acute myeloid leukemia (AML) with 20-30% blasts and multilineage dysplasia
        according to classification of the World Health Organisation (WHO).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are not eligible for haematopoietic stem cell transplantation, who are at
             least 18 years old (no age limit to top) and who have one of the following diseases:

               -  myelodysplastic syndrome (MDS) with intermediate risk 2 or high risk according to
                  the International Prognostic Scoring System (IPSS)

               -  chronic myelomonocytic leukemia (CMML) with 10-29% marrow blasts without
                  myeloproliferative disorder

               -  acute myeloid leukemia (AML) with 20-30% blasts and multilineage dysplasia
                  according to classification of the World Health Organisation (WHO).

        Exclusion Criteria:

          -  Contraindication according to the summary of product characteristics of Vidaza®

          -  Signed patient informed consent form is not available

          -  Patients with advanced malignant hepatic tumors

          -  Pregnant or nursing women, men and women (of childbearing age) who are unwilling to
             apply a reliable method of contraception during and up to three months after treatment
             with Azacitidine

          -  Necessary or planned treatment with other systemic cytostatics

          -  Known medical history of severe decompensatoric cardiac insufficiency

          -  Medical history of clinically unstable cardiac or pulmonary disease

          -  Known or suspected hypersensitivity to azacitidine or mannitol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jürgen Wehmeyer, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hämatologisch-onkologische Gemeinschaftspraxis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>iOMEDICO AG</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2010</study_first_submitted>
  <study_first_submitted_qc>August 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2010</study_first_posted>
  <last_update_submitted>November 12, 2015</last_update_submitted>
  <last_update_submitted_qc>November 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Azacitidin</keyword>
  <keyword>Vidaza</keyword>
  <keyword>Piaza</keyword>
  <keyword>myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>CMML</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>AML</keyword>
  <keyword>daily routine</keyword>
  <keyword>concomitant antiemetic therapy</keyword>
  <keyword>germany</keyword>
  <keyword>non-interventional study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

